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The antidepressant vortioxetine is a 5-HT3-R, 5-HT7-R and 5-HT1D-R antagonist, 5-HT1B-R partial agonist,
5-HT1A-R agonist, and serotonin (5-HT) transporter (SERT) inhibitor. Vortioxetine occupies all targets at
high therapeutic doses and only SERT and 5-HT3-R at low doses. Vortioxetine increases extracellular
monoamine concentrations in rat forebrain more than selective serotonin reuptake inhibitors (SSRI) and
shows pro-cognitive activity in preclinical models. Given its high afﬁnity for 5-HT3-R (Ki ¼ 3.7 nM),
selectively expressed in GABA interneurons, we hypothesized that vortioxetine may disinhibit gluta-
matergic and monoaminergic neurotransmission following 5-HT3-R blockade.
Here we assessed vortioxetine effect on pyramidal neuron activity and extracellular 5-HT concentra-
tion using in vivo extracellular recordings of rat medial prefrontal cortex (mPFC) pyramidal neurons and
microdialysis in mPFC and ventral hippocampus (vHPC). Vortioxetine, but not escitalopram, increased
pyramidal neuron discharge in mPFC. This effect was prevented by SR57227A (5-HT3-R agonist) and was
mimicked by ondansetron (5-HT3-R antagonist) and by escitalopram/ondansetron combinations. In
microdialysis experiments, ondansetron augmented the 5-HT-enhancing effect of escitalopram in mPFC
and vHPC. Local ondansetron in vHPC augmented escitalopram effect, indicating the participation of
intrinsic mechanisms. Since 5-HT neurons express GABAB receptors, we examined their putative
involvement in controlling 5-HT release after 5-HT3-R blockade. Co-perfusion of baclofen (but not
muscimol) reversed the increased 5-HT levels produced by vortioxetine and escitalopram/ondansetron
combinations in vHPC.
The present results suggest that vortioxetine increases glutamatergic and serotonergic neurotrans-
mission in rat forebrain by blocking 5-HT3 receptors in GABA interneurons.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Vortioxetine (Lu AA21004) is an antidepressant with a clinical
efﬁcacy similar to venlafaxine (Alvarez et al., 2012). Vortioxetine
inhibits the serotonin (5-HT) transporter (SERT) and shows high
in vitro afﬁnity for several 5-HT receptors (5-HT-R), including 5-
HT3, 5-HT1A, 5-HT1B and 5-HT7 (Mork et al., 2012; Sanchez et al.,
2015). Vortioxetine has pro-cognitive effects in rodent modelsnd Neuropharmacology, IIBB-
na, Spain.
igas).
dy.
Ltd. This is an open access article u(Betry et al., 2015; Sanchez et al., 2015; Wallace et al., 2014) and its
administration to rodents increases very markedly the extracellular
concentration of monoamines in forebrain (Pehrson et al., 2013) to
an extent greater than that produced by selective serotonin reup-
take inhibitors (SSRI). This difference is most likely due to the
multimodal pharmacological proﬁle of vortioxetine, which may
prevent local (e.g., mediated by 5-HT1A and 5-HT1B autoreceptors)
and distal self-inhibitory mechanisms on monoamine cell groups.
Self-inhibitory mechanisms triggered by 5-HT autoreceptors in
response to antidepressant drug administration were identiﬁed
two decades ago (Artigas et al., 1996, 2001; Pi~neyro and Blier, 1999).
In addition to these local mechanisms, distal loops may also
modulate serotonergic activity. Among them, long distancender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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serotonergic activity (Celada et al., 2001; Hajos et al., 1998; Martin-
Ruiz et al., 2001) and play a major role in the response to behav-
ioural challenges (Warden et al., 2012). The PFC also projects to the
brainstem catecholamine nuclei (Gabbott et al., 2005) and thus,
changes in PFC activity may also evoke downstream changes in the
activity of the ascending dopaminergic and noradrenergic systems.
The PFC contains a high density of neurons expressing 5-HT1A-R
(Santana et al., 2004), whose physiological activation inhibits py-
ramidal neuron activity (Amargos-Bosch et al., 2004; Puig et al.,
2005). Therefore, 5-HT1A-R activation by vortioxetine might
modulate pyramidal output to brainstem catecholamine nuclei and
increase forebrain catecholamine release, as reported for 5-HT1A-R
agonists (Díaz-Mataix et al., 2006; Hajos-Korcsok and Sharp, 1996).
In addition, given the high afﬁnity (3.7 nM) of vortioxetine for 5-
HT3-R (Mork et al., 2012), they may also participate in the distinc-
tive actions of vortioxetine, compared with SSRIs. 5-HT3-R are
present in forebrain GABAergic interneurons that control pyramidal
neuron activity in hippocampus and PFC (Morales and Bloom,1997;
Puig et al., 2004). 5-HT3-R are ion channels and their physiological
activation by endogenous 5-HT markedly excites mPFC GABA in-
terneurons (Puig et al., 2004).
Using single unit recordings in anesthetized rats, we examined
the involvement of 5-HT3-R in the mechanism of action of vorti-
oxetine, under the working hypothesis that 5-HT3 receptor
blockade in GABA interneurons may disinhibit pyramidal neuron
activity in mPFC. Likewise, using in vivo microdialysis in freely-
moving rats, we examined the role of 5-HT3-R blockade as a po-
tential negative feed-back mechanism involved in the control of 5-
HT release during SERT blockade by antidepressant drugs.
2. Material and methods
2.1. Animals and stereotaxic surgery
Male albino Wistar rats (Iffa Credo, Lyon, France) weighing
250e340 g were used. Animal care followed European Union reg-
ulations (directive 2010/63 of September 22, 2010) and was
approved by the Institutional Animal Care and Use Committee.
2.2. Drugs and treatments
Vortioxetine (VOR) hydrobromide and escitalopram oxalate
(ESCI) were provided by H. Lundbeck A/S (Copenhagen-Valby,
Denmark). Ondansetron hydrochloride dihydrate (OND, 5-HT3-R
antagonist), SR57227A (SR, 5-HT3-R agonist), baclofen (BAC,
GABAB-R agonist) and muscimol (MUS, GABAA-R agonist) were
purchased from Sigma-Aldrich (Buchs, Switzerland). Concentrated
stock solutions were prepared in hydroxyl-propyl-ß-cyclodextrin
30% (VOR), saline (for systemic administrations) or artiﬁcial cere-
brospinal ﬂuid (aCSF, for local perfusions) and aliquots were stored
at 20 C. Working solutions were prepared daily by dilution. In
electrophysiological experiments, drugs were administered intra-
venously (i.v.) through the femoral vein. In microdialysis experi-
ments, drugs were administered subcutaneously (s.c.) or locally, by
reverse microdialysis. The doses used were taken from the litera-
ture (Abellan et al., 2000a, 2000b; Betry et al., 2013; Mork et al.,
2012; Zhang et al., 2011) or from pilot experiments.
2.3. Electrophysiological recordings
Electrophysiological recordings were performed as previously
described (Kargieman et al., 2007; Puig et al., 2005) typically be-
tween 9 a.m. and 3 p.m. Rats were anesthetized with chloral hy-
drate (induction: 400mg/kg i.p.]; maintenance: 50e70mg/kg/h i.p.using a perfusion pump) to analyze the responses of layer V mPFC
pyramidal neurons (AP from þ3.4 to þ3.2; ML from 0.5 to 0.9;
DV from 1.5 to 4; mm) (Paxinos and Watson, 2005) to the i.v.
administration of ESC, VOR, OND and SR, alone or in combination.
Pyramidal neurons were identiﬁed by antidromic stimulation from
projection areas of the mPFC such as the dorsal raphe ([DR]; AP
-7,8; L 3,1; DV -6.6 electrode implanted with an angle of 30) or
the ventral tegmental area ([VTA]; AP -5,8; L 0,4; DV -8), followed
by the collision test (Fuller and Schlag, 1976). Both stimulation sites
identify the same population of midbrain-projecting PFC neurons
(Vazquez-Borsetti et al., 2011). DR and VTA were stimulated at
0.5e2.0 mA, 0.2 ms square pulses, 0.9 Hz as previously reported
(Puig et al., 2005). Of the 73 recorded neurons, 62 (85%) projected to
DR, 6 (8%) projected to VTA and 5 (7%) projected to both areas.
Neurons not responding to antidromic activation or without
spontaneous ﬁring activity were discarded.
The recording electrodes were ﬁlled with saline 2M (imped-
ances 6e12 MU). Single unit recordings were ampliﬁed with a
Neurodata IR283 (Cygnus Technology Inc., Delaware Water Gap,
PA), post-ampliﬁed and ﬁltered with a Cibertec ampliﬁer (Cibertec,
Madrid, Spain) and computed on-line using a DAT 1401plus inter-
face system Spike2 software (Cambridge Electronic Design, Cam-
bridge, UK).
Pontamine Sky Blue was added for the identiﬁcation of the
recording site. After obtaining a stable baseline recording for 5 min,
saline or SR was injected as pre-treatment. After 3e5 min, drugs
were administered i.v. Cumulative doses were injected every 3min.
Typically, actual recording time was 23e40 min.2.4. In vivo microdialysis
Microdialysis procedures were conducted as previously
described (Amargos-Bosch et al., 2004). Brieﬂy, anesthetized rats
(sodium pentobarbital, 60 mg/kg i.p.) were stereotaxically
implanted with concentric microdialysis probes equipped with a 4-
mm Cuprophan membrane in the mPFC (AP þ3.2, ML 0.8, DV
e6.0 mm from skull) or ventral hippocampus (vHPC) (AP -5.3, ML
-4.8, DV -8.8 mm from skull). Microdialysis experiments were
carried out in freely-moving rats 20e24 h after surgery at the same
time interval as the electrophysiological experiments. Probes were
continuously perfused with aCSF pumped at 1.5 mL/min. Dialysate
samples of 30 mL were collected every 20 min.
After an initial 60min stabilization period, four baseline samples
were collected before systemic or local pharmacological treat-
ments. In a ﬁrst set of experiments, ESC and OND were adminis-
trated both s.c. to study their effect on extracellular 5-HT in mPFC
and vHPC. In experiments examining the role of hippocampal 5-
HT3-R in augmenting the effect of SERT inhibition on extracellular
5-HT, ESC or VOR was administered s.c. Once a stable effect was
achieved, the perfusion ﬂuid was replaced by one containing OND
and/or BAC (or MUS). Dialysate 5-HT concentrations were analyzed
byHPLC-amperometric detection (Hewlett Packard-1049, Palo Alto,
CA, USA) at þ0.60 V, with detection limit of 2 fmol/sample.2.5. Histology
After experimental procedures were completed, animals were
euthanized by an anaesthetic overdose. The brains were removed,
frozen on dry ice and kept at 80 C before being cut into coronal
sections (50 mm) with a cryostat. Brain sections were stained to
verify the recording and stimulation sites with neutral red or the
correct placement of the probes with fast-green.
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Firing rate was quantiﬁed by averaging the values in 2-min
periods of each experimental period (2nd-3rd min after each drug
cumulative dose administration or 4the5th; 9the10th; 14the15th;
19the20th; 24the25th min after a single dose drug injection).
Neurons were considered to be excited or inhibited when drugs
induced a ±30% change of the discharge rate at least in two
consecutive doses or time periods (Kargieman et al., 2007).
Microdialysis data are given as percentage of basal values,
averaged from 4 pre-drug fractions and also as normalized areas
under curve (AUC) corresponding to every treatment period. The
treatment effects were assessed by one- or two-way repeated
measures ANOVA or Student's t-test, as appropriate, using Statistica
for Windows software (4.5 version) (StatSoft inc.). Post-hoc analysis
was performed using Duncan's test. Data are expressed as
means ± SEM. Statistical signiﬁcance was set at p < 0.05 (two
tailed).3. Results
3.1. Vortioxetine effect on mPFC pyramidal activity. Prevention by
the 5-HT3-R agonist SR57227A
Vortioxetine (VOR; 0.1e0.2e0.4e0.8e1.6 mg/kg i.v., cumulative
doses) dose-dependently increased the ﬁring rate in 10 (77%) of the
13 neurons recorded. Two neurons (15%) were unaffected and
another one (8%) decreased its activity. Maximal effect was
observed at 0.4 mg/kg i.v. The increased discharge rate persisted forFig. 1. Effect of vortioxetine (VOR) on the ﬁring rate of layer V (midbrain-projecting) pyram
agonist SR57227A (SR). A) Representative example of a pyramidal neuron whose discharg
cumulative doses). B) and C) Bar graphs showing the average effect of VOR on ﬁring rate i
Representative example of the prevention of VOR effect on mPFC pyramidal discharge by p
agonist SR57227A on pyramidal discharge. E) Bar graph showing the lack of VOR effect in
comparison between saline (SAL) þ vortioxetine (SAL þ VOR) and SR57227A þ vortioxetine
#p < 0.003 SAL versus SR57227A pre-treatments at VOR doses of 0.4, 0.8 and 1.6 mg/kg i.v13 min after the last VOR injection. Fig. 1A shows a representative
example of VOR effect on the discharge of an mPFC pyramidal
neuron. Fig. 1B and C shows the effect of VOR in all neurons
(231 ± 44% of baseline, n¼ 13) and in activated neurons (273 ± 51%
of baseline, n¼ 10). One-way ANOVA revealed a signiﬁcant effect of
VORwhen considering all neurons (F(6,72)¼ 3.00; p < 0.02, n¼ 13)
or only excited neurons (F(6,54) ¼ 3.21; p < 0.01, n ¼ 10) and post-
hoc differences between VOR (0.4e0.8e1.6 mg/kg i.v.) and
baseline-saline values.
Given the high afﬁnity of VOR for 5-HT3-R, we studied the po-
tential prevention of its effect by the 5-HT3-R agonist SR57227A by
comparing SR57227A þ VOR versus SAL þ VOR. A single dose
(1.28 mg/kg i.v.) of SR57227A fully prevented the elevation of py-
ramidal cell ﬁring induced by VOR. Two-way ANOVA revealed
signiﬁcant effects of pre-treatment (F(1,22) ¼ 4.41; p < 0.05),
treatment (F(6,132) ¼ 4.03; p < 0.002) and pre-treatment$treat-
ment interaction (F(6,132) ¼ 2.83; p < 0.02 n ¼ 13 and 11 for
SAL þ VOR, and SR57227A þ VOR groups, respectively), with sig-
niﬁcant post-hoc differences between SAL and SR57227A pre-
treatments at VOR doses of 0.4, 0.8 and 1.6 mg/kg i.v. Fig. 1D
shows a representative example of the lack of an effect of cumu-
lative doses of VOR in SR57227A-pre-treated rats. Fig. 1E shows the
prevention by SR57227A of VOR effect in all neurons. The preven-
tion of VOR effect by SR57227A was observed in 10 of the 11 py-
ramidal neurons. Fig. 1F shows the dose-effect relationships for
both experimental groups.idal neurons in rat medial prefrontal cortex (mPFC) and its prevention by the 5-HT3-R
e was increased by intravenous VOR administration (0.1e0.2e0.4e0.8e1.6 mg/kg i.v.,
n all neurons (B, n ¼ 13) and in the subpopulation of excited neurons (C, n ¼ 10). D)
re-treatment with SR57227A (1.28 mg/kg, i.v.). Note the lack of effect of the 5-HT3-R
SR57227A pre-treated rats in all recorded neurons (n ¼ 11). F) Graph showing the
(SR þ VOR) groups. *p < 0.05 versus basal (BAS) and SAL values in SAL þ VOR group;
.
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activity in mPFC
The administration of escitalopram (ESC,
0.1e0.2e0.4e0.8e1.6 mg/kg i.v., cumulative doses) did not alter the
discharge rate of mPFC pyramidal neurons (n ¼ 9). Five neurons
(55.5%) were not signiﬁcantly activated, 3 were unaffected (33.3%)
and 1 was inhibited (11.2%). Fig. 2A and B shows a representative
example and the effect of ESC in all recorded neurons, respectively.Fig. 2. Effects of escitalopram (ESC, a selective serotonin reuptake inhibitor, SSRI), ondanse
(ESC þ OND) on pyramidal neuron activity in mPFC. A) Example of a pyramidal n
(0.1e0.2e0.4e0.8e1.6 mg/kg i.v.). B) Bar graph showing the average effect of ESC on ﬁring r
single dose of ESC (0.1 mg/kg i.v., n ¼ 8) during a 25-min period after drug administration. D
doses administration (0.32e0.64e1.28 mg/kg i.v.). E) and F) Bar graphs showing the avera
population (F, n ¼ 7). G) and H) Examples of two pyramidal neurons showing an increase G
showing the increasing effect on pyramidal activity of single dose of OND in all neurons
pyramidal neuron response to the administration of the drug combination ESC (0.1 mg/kg i
OND on pyramidal activity in all neurons (n ¼ 9) and in excited neuron subpopulation (n ¼
and escitalopram þ ondansetron (ESC þ OND) groups. *p < 0.05 vs Basal and SAL value
100e150e200e250 min after administration versus OND (10e15e20e25 min after administraSimilarly, a single dose of ESC (0.1 mg/kg i.v.) did not affect the
ﬁring rate of mPFC pyramidal neurons (n¼ 8). Five neurons (62.5%)
were not signiﬁcantly inhibited by ESC, 1 (12.5%) was unaffected
and 2 (25%) were not signiﬁcanty activated. Fig. 2C shows the effect
of a single dose of ESC in all recorded neurons.
The administration of ondansetron (OND; 0.16e0.32e1.28 mg/
kg i.v., cumulative doses) evoked a dose-dependent increase in
pyramidal discharge in 7 out of 11 neurons (63.6%) recorded (4
were unaffected; 36.4%). The maximal effect was achieved attron (OND, a 5-HT3-R antagonist) and the combination of escitalopram þ ondansetron
euron whose discharge was unaffected by ESC cumulative doses administration
ate in all neurons (n ¼ 9). C) Graph showing the lack of effect of the administration of a
) Example of a pyramidal neuron whose discharge was augmented by OND cumulative
ge effect of OND on ﬁring rate in all neurons (E, n ¼ 11) and in excited neuron sub-
) or a lack of effect H) after OND administration (1.28 mg/kg i.v., single dose). I) Graph
(n ¼ 9) and in excited neuron subpopulation (n ¼ 6). J) Representative example of a
.v.) þ OND (1.28 mg/kg i.v.). K) Graph showing the increasing effect of a single dose of
6). L) Graph showing the comparison between escitalopram (ESC), ondansetron (OND)
s in OND (single and cumulative doses) and ESC þ OND groups; #p < 0.05 ESC at
tion) and ESC þ OND (5e10e15e20e25 min after administration).
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vated neuron. Fig. 2E and F shows the effect of OND in all neurons
(239 ± 55% of baseline, n ¼ 11) and in activated neurons (311 ± 74%
of baseline, n ¼ 7). One-way ANOVA revealed a signiﬁcant effect of
ONDwhen considering all neurons (F(4,40)¼ 2.91; p < 0.05, n¼ 11)
or only excited neurons (F(4,24) ¼ 3.31; p < 0.03, n ¼ 7) with post-
hoc differences between OND (1.28 mg/kg i.v.) and baseline-saline
values. The increased discharge rate persisted for 20 min after
the last OND injection. Similarly, a single dose of OND (1.28 mg/kg
i.v.) increased the ﬁring rate in 6 of the 9 (66.7%) pyramidal neurons
recorded. Two neurons (22.2%) were inhibited and 1 (11.1%) was
unaffected. Maximal effect was observed at 10 min post-
administration and persisted for the duration of recordings (typi-
cally 25 min post-administration). Fig. 2 shows representative ex-
amples of activated (2G) and unaffected (2H) neurons. Fig. 2I shows
the effect of OND in all neurons (253 ± 73% of baseline, n¼ 9) and in
the subgroup of excited neurons (333 ± 94% of baseline, n ¼ 6).
One-way ANOVA indicated a signiﬁcant effect of the treatment for
all neurons (F(6,48)¼ 2.28; p < 0.03; n¼ 9) or only excited neurons
(F(6,30) ¼ 4.18; p < 0.005; n ¼ 6), with post-hoc differences be-
tween OND (1.28 mg/kg i.v. at 10e15e20e25 min after adminis-
tration) and baseline-saline values.
In order to further clarify the role of 5-HT3-R in the enhancing
effect on pyramidal activity by VOR, we evaluated the action of
ESC þ OND (to mimic the mechanism of action of VOR). This drug
combination evoked an increase in the ﬁring rate in 9 out of 12
(75%) recorded neurons. Three neurons (25%) were unaffected. The
combination of OND þ ESC increased pyramidal neuron discharge
to an extent similar to OND alone. Maximal effect was observed at
10 min post-administration and persisted for the duration of re-
cordings (25 min post-administration). Fig. 2J shows a represen-
tative example of an activated neuron. Fig. 2K shows the effect of
the drug combination in all neurons (290 ± 52% of baseline, n ¼ 12)
and in the subgroup of excited neurons (357 ± 53% of baseline,
n ¼ 9). One-way ANOVA indicated a signiﬁcant effect of treatment
considering all neurons (F(6,66) ¼ 5.88; p < 0.0001; n¼ 12) or only
excited neurons (F(6,48) ¼ 7.41; p < 0.00001; n ¼ 9), with post-hoc
differences between ESC þ OND at 5e10e15e20e25 min post-
administration and baseline-saline values.
Finally, we compared the effects on the mPFC pyramidal
discharge induced by the three treatments (ESC, OND, ESC þ OND).
Two-way ANOVA (with time and treatment as factors) revealed a
signiﬁcant effect of time (F(6,156) ¼ 7.73; p < 0.00001), treatment
(F(2,26) ¼ 3.53; p < 0.05) and treatment  time interaction
(F(12,156) ¼ 1.90; p < 0.05) (n ¼ 8, 9 and 12 for ESC, OND and
ESC þ OND groups, respectively), with post-hoc differences be-
tween OND or ESC þ OND and ESC (Fig. 2L).
3.3. Effect of systemic administration of ESC and OND on
extracellular 5-HT concentration in mPFC and vHPC
OND administration (10 mg/kg s.c.) had no effect alone but
augmented the effect of ESC (3.2mg/kg s.c.) on extracellular 5-HT in
mPFC (Fig. 3AeB) and vHPC (Fig. 3CeD). In mPFC, two-way ANOVA
for repeated measures of AUC values revealed signiﬁcant effects of
group (F(3,25) ¼ 11.38; p < 0.00001), treatment (F(2,50) ¼ 17.01;
p < 0.00001) and treatment$group interaction (F(6,50) ¼ 8.69;
p < 0.00001, n¼ 4, 6, 10 and 9 for SALþ SAL, SALþ OND, ESCþ SAL
and ESC þ OND groups, respectively) with signiﬁcant post-hoc
differences between ESCþ OND and ESC. In vHPC, two-way ANOVA
for repeated measures of AUC values also revealed signiﬁcant ef-
fects of group (F(3,27) ¼ 10.76; p < 0.0001), treatment
(F(2,54) ¼ 11.26; p < 0.0001) and treatment$group interaction
(F(6,54) ¼ 9.10; p < 0.00001, n ¼ 5, 5, 9 and 12 for SAL þ SAL,
SAL þ OND, ESC þ SAL and ESC þ OND groups, respectively) withsigniﬁcant post-hoc differences between ESC þ OND and ESC.
3.4. Relevance of local 5-HT3-R in vHPC on vortioxetine effect on
extracellular 5-HT: involvement of GABAB-R
To examine the potential involvement of local 5-HT3-R
econtaining microcircuits in vHPC in the augmentation of ESC ef-
fects by systemic OND, we examined the ability of local OND
infusion in vHPC (300 mM in aCSF) to augment the effect of ESC
(3.2 mg/kg s.c.) on extracellular 5-HT (Fig. 4A and B). The s.c. ESC
administration increased extracellular 5-HT in vHPC toz3-fold the
basal levels. This effect was sustained, lasting for z15 fractions
(300min). The local application of 300 mMOND in vHPC produced a
robust potentiation of ESC effect. Two-way ANOVA for repeated
measures of AUC values revealed signiﬁcant effects of group
(F(1,12) ¼ 7.75; p < 0.02), treatment (F(2,24) ¼ 42.13; p < 0.00001)
and treatment$group interaction (F(2,24) ¼ 9.97; p < 0.001 n ¼ 7
for both ESC and ESC þ OND groups), with signiﬁcant post-hoc
differences between ESC and ESC þ OND. Local OND application
alone increased the extracellular 5-HT concentration in vHPC
(380 ± 8% of basal values; p < 0.03; n ¼ 5) (Fig. 4C).
Unlike mPFC, the vHPC lacks afferent pathways to the raphe
nuclei that may explain the OND augmentation of ESC effect, thus
suggesting the involvement of local microcircuits in this effect. We
then hypothesized that 5-HT3-R blockade by OND and VOR would
reduce GABA release and consequently, the GABA tone on local
GABAB-R controlling 5-HT release. We then examined whether the
restoration of the GABAB-R tone with baclofen (BAC) could atten-
uate the augmenting effect of OND on extracellular 5-HT. The local
co-perfusion of BAC (100 mM) by reverse dialysis in vHPC fully
reversed the increase of extracellular 5-HT produced by the local
application of OND after systemic ESC administration, and nor-
malised 5-HT values (Fig. 4D and E). One-way ANOVA for repeated
measures of AUC values revealed signiﬁcant effect of treatment
(F(3,15) ¼ 10.79; p < 0.0005; n ¼ 6), with signiﬁcant post-hoc dif-
ferences between ESC, ESC þ OND and ESC þ OND þ BAC treat-
ments. Moreover, the local perfusion of BAC did not alter ESC-
induced increase of extracellular 5-HT (Fig. 4F). One-way ANOVA
for repeated measures of AUC values revealed signiﬁcant effect of
treatment (F(2,10) ¼ 4.77; p < 0.05; n ¼ 6), with no post-hoc dif-
ferences between ESC and ESC þ BAC treatments.
Similarly, local BAC infusion (100 mM in aCSF) by reverse dialysis
in vHPC attenuated the effect of VOR (5 mg/kg s.c.) on extracellular
5-HT. Unlike BAC, local administration of the GABAA-R agonist
muscimol (MUS) in vHPC (100 mM in aCSF) failed in reversing VOR
effect on extracellular 5-HT (Fig. 4G and H). Two-way ANOVA for
repeated measures of AUC values revealed signiﬁcant effects of
group (F(2,18) ¼ 9.15; p < 0.002), treatment (F(2,36) ¼ 53.29;
p < 0.00001) and the treatment$group interaction (F(4,36)¼ 14.72;
p < 0.00001 n ¼ 9, n ¼ 7 and n ¼ 5 for VOR, VOR þ BAC and
VOR þ MUS, respectively) with signiﬁcant post-hoc differences
between VOR or VOR þ MUS and VOR þ BAC treatments.
4. Discussion
The present results indicate that acute vortioxetine adminis-
tration dose-dependently increased the discharge rate of mPFC
pyramidal neurons projecting tomidbrain, with a maximal effect at
0.4mg/kg i.v. In contrast, escitalopram did not signiﬁcantly alter the
same neuronal population at doses that fully block SERT (vortiox-
etine: Betry et al., 2013; escitalopram: unpublished observations).
Likewise, vortioxetine increased extracellular 5-HT concentration
in mPFC and vHPC to an extent greater than that evoked by esci-
talopram. This difference is likely due to the simultaneous blockade
of SERT and 5-HT3-R by vortioxetine, since its effects were
Fig. 3. Effect of systemic administration of escitalopram (ESC) and ondansetron (OND) on extracellular 5-HT concentration in medial prefrontal cortex (mPFC) and ventral hip-
pocampus (vHPC). The subcutaneous (10 mg/kg) administration of OND augments the enhancing effect of ESC (3.2 mg/kg s.c.) on extracellular 5-HT in mPFC (A and B) and vHPC (C
and D). Note the lack of effect of OND by itself in both areas. A) and C) Graphs show data as % of basal values averaged from 4 pre-drug fractions during two 120-min post-drug
administration periods in mPFC (A) and vHPC (C). B) and D) Results are also represented as normalized areas under curve (AUC) corresponding to each treatment period for mPFC B)
and vHPC C). The experimental groups performed for each area are: escitalopram þ ondansetron (ESC þ OND), escitalopram þ saline (ESC þ SAL), saline þ ondansetron (SALþ OND)
and saline þ saline (SALþ SAL). Arrows mark ﬁrst and second drug administrations. *p < 0.01 versus Basal values; #p < 0.05 versus ESC in ESC þ OND group; a p < 0.0001 ESC þ OND
versus ESC þ SAL periods.
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escitalopram and ondansetron combinations (and by ondansetron
alone for pyramidal discharge elevations).
We suggest that vortioxetine blockade of 5-HT3-R disinhibits
pyramidal neuron activity and 5-HT release following the removal
of the GABAergic tone on pyramidal neurons (mainly mediated by
GABAA-R) and on 5-HT nerve terminals (mediated by GABAB-R)
(Fig. 5). Hence, unlike SSRI, vortioxetine increased the gluta-
matergic/GABAergic neurotransmission ratio in rat brain. These
effects may explain the superior effects of vortioxetine in various
experimental models, such as neurotransmitter release (Pehrson
et al., 2013) and pro-cognitive effects in rodents (Betry et al.,
2015; Sanchez et al., 2015; Wallace et al., 2014).
5-HT3-Rs are exclusively expressed in GABAergic interneurons
in cortical and hippocampal areas (Lee et al., 2010; Morales and
Bloom, 1997; Puig et al., 2004). 5-HT3-R have also been identiﬁed
in GABAergic interstitial cells of the corpus callosum, which may
control cortical and subcortical networks (von Engelhardt et al.,
2011). Cortical GABAergic interneurons activate GABAA-R to
rapidly control electrical and biochemical signalling in pyramidal
neurons. GABAergic interneurons are classiﬁed according to their
morphology, connectivity, electrophysiological properties and
expression proﬁle of neuropeptides and calcium binding proteins,
such as parvalbumin (PV), calbindin or calretinin (DeFelipe et al.,
2013). PV-positive neurons are a subpopulation of GABAergic cells
comprising chandelier and large basket cells (DeFelipe, 1997) that
tightly control neuronal activity via axo-somatic (basket cells) or
axo-axonic (chandelier cells) synapses on deep layer pyramidal
neurons (DeFelipe and Fari~nas, 1992). In the mPFC, 5-HT3-R are
expressed in non-PV, non-somatostatin GABAergic interneurons,located in upper cortical layers (Lee et al., 2010; Morales and Bloom,
1997; Puig et al., 2004), which include neurogliaform cells (Olah
et al., 2009; Tamas et al., 2003) and VIP-expressing interneurons
(Lee et al., 2013; Pi et al., 2013). The percentage of mPFC GABAergic
neurons expressing 5-HT3-R is 40% in layer I, 18% in layers II-III, 6%
in layer V and 8% in layer VI (Puig et al., 2004). Given their pre-
dominant location in superﬁcial layers, we expected that 5-HT3-R
blockade would have a moderate impact on the activity of
midbrain-projecting pyramidal neurons, located in layers V-VI
(Gabbott et al., 2005). However, z 70% of the recorded pyramidal
neurons showed a marked increase of their discharge rate after 5-
HT3-R blockade with vortioxetine or ondansetron.
Several reasons may account for this apparent discrepancy. On
the one hand, 5-HT3-R are ion channels and their physiological
stimulation by 5-HT markedly increased the discharge of 5-HT3-R-
expressing GABAergic interneurons in mPFC (Puig et al., 2004). In
agreement, the microiontophoretic and systemic administration of
5-HT3-R agonists decreased the ﬁring activity of putative pyramidal
neurons in mPFC (Ashby et al., 1991; Bachy et al., 1993; Edwards
et al., 1996). Similar effects have been reported in the hippocam-
pus after the physiological release of 5-HT or local application of 5-
HT3-R agonists (Varga et al., 2009). Hence, 5-HT3-R-expressing in-
terneurons may inhibit pyramidal activity more than anticipated
from their location in superﬁcial and middle layers due to the ionic
nature of 5-HT3-R. On the other hand, 5-HT3-R may be present in
GABAergic interneurons controlling pyramidal neuron activity via
axo-somatic contacts (Freund, 2003; Marlin and Carter, 2014) and/
or in cortical networks of synaptically- and electrically-coupled
interneurons (Galarreta and Hestrin, 2001; Tamas et al., 2003;
Traub et al., 2001).
Fig. 4. Relevance of local hippocampal microcircuits containing 5-HT3-R in vortioxetine effect on extracellular 5-HT. Involvement of GABAB-R. A) and B) Graphs (A % of basal values;
B AUCs) showing the potentiating effect of local infusion in vHPC of the 5-HT3-R antagonist ondansetron (OND, 300 mM) on the augmenting in extracellular 5-HT concentration
induced by systemic administration of escitalopram (ESC, 3.2 mg/kg s.c.) in freely-moving rats. Note that the local administration of OND alone increases the extracellular 5-HT
concentration in vHPC (C). D) and E) The local co-perfusion of baclofen (BAC, 100 mM) by reverse dialysis in vHPC reverses the increase of extracellular 5-HT produced by the
local application of OND after systemic ESC administration. Data are represented as % of basal values (D) or as AUC.(E). Note that the local administration of BAC alone does not alter
the effect induced by the systemic administration of ESC (F). G) (% of basal values) and H) (AUCs) Local BAC infusion (100 mM in aCSF) in vHPC (but not muscimol, MUS, 100 mM in
aCSF) attenuates the effect of systemic VOR (5 mg/kg s.c.) on extracellular 5-HT levels. *p < 0.05 vs Basal values; #p < 0.03 ESC versus ESC þ OND; a p < 0.03 ESC þ OND versus
ESC þ OND þ BAC; b p < 0.0001 VOR þ BAC versus VOR and VOR þ MUS.
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rapid ionotropic action of 5-HT on a subpopulation of cortical and
hippocampal interneurons through the activation of 5-HT3-R. The
present observations suggest that 5-HT3-R are tonically activated
by 5-HT in the anesthetized rat since both vortioxetine and
ondansetron elevated pyramidal neuron discharge. Given the
presence of an excitatory control of the mPFC on 5-HT neuronal
activity (Celada et al., 2001; Hajos et al., 1998), it is likely that the
actions of vortioxetine in mPFC may contribute to the rapid re-
covery of serotonergic cell ﬁring observed after repeated vortiox-
etine treatment (Betry et al., 2013; Sanchez et al., 2015).
The increased pyramidal discharge induced by vortioxetine in
mPFC may also be involved in its pro-cognitive effect in rodents
(Betry et al., 2015; Sanchez et al., 2015; Wallace et al., 2014). The
PFC is critically involved in cognition, including working memory
and executive functions (Miller and Cohen, 2001). Primate studies
have revealed that the neurobiological substrate of working
memory is the maintenance of patterns of persistent neuronalactivity in the dorsolateral PFC (equivalent to the prelimbic mPFC in
rodents) during mnemonic processes (Curtis and D'Esposito, 2003;
Fuster and Alexander, 1971). Hence, the increased pyramidal
discharge induced by vortioxetine may facilitate the emergence
and maintenance of these activity patterns during working mem-
ory tasks.
Another distinctive feature of vortioxetine is its ability to in-
crease extracellular monoamine concentrations above the level
produced by SSRI (Pehrson et al., 2013). Here we provide evidence
that, at least for 5-HT, this effect is likely due to the removal of a
GABAB-R tone on 5-HT terminals following 5-HT3-R blockade in
local interneurons. Ondansetron augmented the effect of escitalo-
pram on extracellular 5-HT in mPFC and vHPC, indicating that 5-
HT3-R blockade can facilitate 5-HT release following SERT inhibi-
tion in both areas. Further experiments were carried out in vHPC,
which -unlike mPFC- lacks direct afferent pathways to midbrain
raphe, thus avoiding potential confounding effects due to the distal
modulation of serotonergic neuron activity. Local ondansetron
Fig. 5. Schematic representation of the putative actions of vortioxetine on pyramidal
neuron discharge and on 5-HT release. The blockade of 5-HT3-R located on GABA in-
terneurons reduces GABA input onto GABAA-R controlling the activity of mPFC pyra-
midal neurons, thus enhancing their discharge rate. Likewise, blockade of 5-HT3-R
reduces the GABA tone on terminal GABAB-R controlling 5-HT release by nerve ter-
minals, therefore augmenting the effect of SERT blockade on extracellular 5-HT (see
text for an extended discussion).
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cellular 5-HT, suggesting the existence of local microcircuits that
attenuate 5-HT release via 5-HT3-R activation. Raphe 5-HT neurons
express GABAB-R (Abellan et al., 2000a), which exert a biphasic
control of 5-HT neuronal activity and 5-HT release (Abellan et al.,
2000b; Tao et al., 1996). In control conditions, stimulation of ter-
minal GABAB-R did not affect striatal 5-HT release (Abellan et al.,
2000), possibly due to the existence of a tonic control by endoge-
nous GABA. However, the present results suggest that the removal
of the GABA tone on hippocampal GABAB-R disinhibits 5-HT
release, and that the restoration of the tone by the prototypical
GABAB-R agonist baclofen -but not the GABAA-R agonist muscimol-
attenuates 5-HT release (see Fig. 4H).5. Conclusions
In summary, the present study indicates that vortioxetine has
strong antagonist effects on 5-HT3-R which add on top of SERT
inhibition to evoke a robust disinhibition of pyramidal neuron ac-
tivity in mPFC and of 5-HT release in forebrain. Since vortioxetine
shows afﬁnity for various 5-HT-R, an additional role of other re-
ceptors (e.g., 5-HT1A-R, 5-HT1B-R, 5-HT7-R) cannot be discarded.
However, it is likely that the simultaneous blockade of SERT and 5-
HT3-R accounts for the differential actions of vortioxetine in ro-
dents, compared to SSRIs, such as the greater increase in extracel-
lular monoamine concentrations and the pro-cognitive actions. The
present results also show that, in addition to 5-HT1A and 5-HT1B
autoreceptors, forebrain serotonergic activity is tonically limited by
the activation of 5-HT3-R in GABAergic interneurons. The latter
inhibitory effect can be exerted at the local level (e.g., by negatively
modulating 5-HT release) or distally, via the attenuation of mPFC-
midbrain excitatory pathways after the stimulation of 5-HT3-R in
GABAergic interneurons. The attenuation of these negative feed-mechanisms may improve serotonergic activity and therefore, the
treatment of major depression.
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